SkyView Investment Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

SkyView Investment Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,183	Closed	-$32K	–	847
2022 Q4	$32K	Hold	3,183	–	–	0.01%	389
2022 Q3	$32K	Hold	3,183	–	–	0.01%	425
2022 Q2	$32K	Buy	+3,183	New	+$31.2K	0.01%	464

SkyView Investment Advisors's BIOT Position: Q1 2023 in Review

SkyView Investment Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 3,183 shares — an estimated $32K sold.

SkyView Investment Advisors first reported a position in BIOT in Q2 2022 and held it in 3 quarters. The position peaked at $32K in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

SkyView Investment Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
SkyView Investment Advisors sold 3,183 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $32K.
SkyView Investment Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2022 and held it in 3 quarters.
SkyView Investment Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $32K in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on SkyView Investment Advisors's 13F filing for Q1 2023, filed 18 May 2023.